Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;76(1):191-209.
doi: 10.1111/all.14494. Epub 2020 Sep 6.

Economic considerations on the usage of biologics in the allergy clinic

Pauline Azzano  1 , Élise Dufresne  1 , Thomas Poder  2   3 , Philippe Bégin  1
Affiliations
Review

Economic considerations on the usage of biologics in the allergy clinic

Pauline Azzano et al. Allergy. 2021 Jan.

Abstract

The advent of biologic therapies has transformed care for severe atopic disorders but their high cost poses new challenges with regard to long-term sustainability and fair allocation of resources. This article covers the basic concepts of cost-utility analyses and reviews the available literature on cost utility of biologic drugs in atopic disorders. When used within their limits as part of a multi-dimensional assessment, economic analyses can be extremely useful to guide decision-making and prioritization of care. Despite the good quality of most cost-utility analyses conducted for the use of biologics in asthma and other atopic diseases, their conclusions regarding cost-effectiveness are extremely variable. This is mainly due to the use of inconsistent estimates of health utility benefit with therapy. Development of reliable and validated instruments to measure disutility in atopic disorders and measure of indirect costs in atopic disease are identified as a priority for future research.

Keywords: allergy; asthma; biologics; cost utility; cost-effectiveness.

PubMed Disclaimer

References

REFERENCES

    1. Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price!. BioDrugs. 2020;34(2):159-170.
    1. Miller S. The $250 billion potential of biosimilars. 2013; http://lab.express-scripts.com/lab/insights/industry-updates/the-$250-bi.... Accessed July 29, 2019
    1. Sanders GD, Maciejewski ML, Basu A. Overview of cost-effectiveness analysis. JAMA 2019;321(14):1400.
    1. Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med 2017;376(3):203-205.
    1. Kadom N, Itri JN, Trofimova A, Otero HJ, Horny M. Cost-effectiveness analysis: an overview of key concepts, recommendations, controversies, and pitfalls. Acad Radiol. 2019;26(4):534-541.

Substances